Ozempic® is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established CV disease. Body weight reduction was a secondary endpoint in clinical trials.
The licensed indication for Ozempic is in the management of Type 2 Diabetes - either as monotherapy or in combination with other treatments.
Weight loss as a secondary outcome has been, and continues to be extensively studied.
Please be mindful of the below warnings and be sure to familiarise yourself with the patient information leaflet included with your medication.
Patients who have a BMI of at least 28 with medical conditions or above 30 without, or have high blood pressure or high blood glucose can take this medication - our pharmacist will discuss further.
This medication is NOT suitable for the following patient groups:
Risk of Thyroid C-Cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
Pancreatitis: Acute and chronic pancreatitis have been reported in clinical studies. You should be mindful of the signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Ozempic® promptly, and if pancreatitis is confirmed, do not restart.
Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic® (3.0%) compared with placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycaemic control with semaglutide on diabetic retinopathy complications has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
Never Share an Ozempic® Pen Between Patients: Ozempic® pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
Hypoglycaemia: The risk of hypoglycaemia is increased when Ozempic® is used in combination with insulin secretagogues (eg, sulphonylureas) or insulin.
Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require haemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhoea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions. - You may be invited to undertake a blood test, our pharmacist will let you know what the procedure will be.
Hypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.
Foetal Abnormalities - There is a risk of foetal abnormalities and other pregnancy related conditions when taking during pregnancy - for this reason, Ozempic should NOT be taken during pregnancy unless under strict supervision, it must also be discontinued 2 months before conception due to the long half life.
Administer Ozempic® once weekly on the same day each week, at any time of the day, with or without meals
The day of weekly administration can be changed if necessary as long as the time between 2 doses is at least 2 days (>48 hours)
If a dose is missed, administer Ozempic® as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, you can then resume your regular once-weekly dosing schedule.
Inject into the abdominal fat, thigh or upper arm - our pharmacist will go through this in detail with you.
Watch a full video review - Here
The most common side effects of Ozempic® may include nausea, diarrhea, vomiting, stomach (abdominal) pain, and constipation. The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose increases.
You have to be authenticated to write a review